GLP-1 Drug Makers Face Lawsuits Over Alleged Vision Loss Risks
Hundreds of patients filed lawsuits against GLP-1 drug makers Novo Nordisk and Eli Lilly, alleging sudden vision loss linked to medications like Ozempic and Mounjaro.
Hundreds of patients have filed lawsuits against GLP-1 drug manufacturers, widely known as weight-loss and diabetes medications, alleging that use of the treatments led to sudden vision loss. The legal actions, targeting companies such as Novo Nordisk and Eli Lilly, accuse the manufacturers of failing to adequately warn patients that their products may be linked to non-arteritic anterior ischemic optic neuropathy (NAION), a medical condition caused by reduced blood flow to the optic nerve that can result in permanent damage.
Legal Claims and Patient Testimonies
According to reports cited by USA Today, plaintiffs claim they developed the syndrome after using medications including Ozempic, Wegovy, Mounjaro, Zepbound, and Trulicity. Among the plaintiffs is a 63-year-old diabetic man who began taking Ozempic in 2023 and lost vision in one eye approximately four months later. Unaware of the underlying cause, he continued taking the medication and subsequently lost vision in his second eye in 2024, leaving him legally blind. The central argument presented by the plaintiffs is that they were not provided with the necessary data to accurately assess the risks to their vision.
Data from the Cleveland Clinic indicates that vision-related complications associated with these drugs are a rare phenomenon leading to sudden, painless vision loss. Currently, there is no proven treatment to reverse the condition, although some patients experience gradual improvement. Legal experts note significant hurdles in proving direct causality, as diabetes and other underlying health conditions independently increase the risk of eye disorders, meaning that diagnosis following drug use does not inherently establish causation.
Regulatory Responses and Manufacturer Stances
Labeling and warning requirements remain at the center of the dispute. In 2025, European regulators determined that specific optic nerve complications represent a very rare side effect of semaglutide, the active ingredient in Ozempic and Wegovy, and initiated updates to product packaging inserts.
"Novo Nordisk stated that the company did not identify a risk of the syndrome in its randomized clinical trials and dismissed the lawsuits as meritless."
Eli Lilly responded by emphasizing that patient safety remains its highest priority and that it continuously monitors reports concerning its pharmaceutical portfolio. Meanwhile, ophthalmology experts noted in an August 2026 update that the overall risk of the condition among GLP-1 users remains low.
